Virtual Congress On News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atemwegsinfekte im Winter: Infektiologen mit Prognose zurückhaltend

Atemwegsinfekte im Winter: Infektiologen mit Prognose zurückhaltend
aerztezeitung.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aerztezeitung.de Daily Mail and Mail on Sunday newspapers.

Mathias pletzA working group hasVirtual congress onProfessor lotharFrom robertVirtual congressSouthern hemisphereThere areWorking group hasRespiratory syncytialHousehold infectiologist professor mathias pletzProfessor andreasDiseases such as corona

Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement

Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomS lale tokgJeanine roetersDutch lipid clinical networkImperial college londonEuropean society of cardiologyImperial centre for cardiovascular disease preventionErasmus medical centerEuropean atherosclerosis societyVirtual congress onHacettepe universityImperial centreCardiovascular disease preventionImperial collegeMedscape cardiology

Simple Risk Assessment Predicts Post-PCI Ischemic Events

Simple Risk Assessment Predicts Post-PCI Ischemic Events
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

S lale tokgZhaoyu wangJ atheroscler thrombEuropean association for cardiothoracic surgeryNational centerEuropean society of cardiologyVirtual congress onEuropean atherosclerosis societyVirtual congressHacettepe universityEuropean associationCardiothoracic surgeryMyocardial revascularizationCardiovascular diseasesFuwai hospitalMedscape cardiology

Results from IMBRUVICA® RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia

ABBVie , today announced extended long-term data from the Phase 3 RESONATE-2 study evaluating single-agent IMBRUVICA versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma . 1 These data will be presented on June 4 th during the 2021 American Society of Clinical Oncology Annual Meeting . Additionally, new data will be presented during the .

United statesPaulm barrDanelle jamesImbruvica global developmentAbbvie companyJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationEuropean heamtology associationAmerican society of clinical oncology annual meetingUniversity of rochesterAbbvie incVirtual congress onWilmot cancer instituteVirtual congressNational comprehensive cancer network

Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)

/PRNewswire/ AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent.

United statesPaulm barrAbbvie companyJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationExchange commissionEuropean heamtology associationAmerican society of clinical oncology annual meetingUniversity of rochesterAbbvie incVirtual congress onWilmot cancer instituteVirtual congressNational comprehensive cancer networkClinical oncology